Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,111,594
  • Shares Outstanding, K 124,758
  • Annual Sales, $ 484,330 K
  • Annual Income, $ -8,350 K
  • 60-Month Beta 0.86
  • Price/Sales 2.51
  • Price/Cash Flow 51.48
  • Price/Book 1.12
Trade NEO with:

Options Overview Details

View History
  • Implied Volatility 94.77% ( -57.39%)
  • Historical Volatility 105.91%
  • IV Percentile 83%
  • IV Rank 38.84%
  • IV High 185.46% on 05/11/22
  • IV Low 37.17% on 09/16/21
  • Put/Call Vol Ratio 0.68
  • Today's Volume 326
  • Volume Avg (30-Day) 321
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 52,514
  • Open Int (30-Day) 48,520

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -575.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.26 +22.45%
on 05/12/22
12.27 -27.55%
on 04/19/22
-3.42 (-27.78%)
since 04/14/22
3-Month
7.26 +22.45%
on 05/12/22
21.94 -59.48%
on 03/01/22
-11.43 (-56.25%)
since 02/17/22
52-Week
7.26 +22.45%
on 05/12/22
54.74 -83.76%
on 10/01/21
-28.74 (-76.38%)
since 05/17/21

Most Recent Stories

More News
Lost Money in NeoGenomics, Inc.?

Shares of NeoGenomics Inc. dropped more than 20% on March 28th, 2022, after the company announced disappointing guidance in its quarterly report, in addition to the departure of its CEO Mark Mallon. Gibbs...

NEO : 8.89 (-0.22%)
NeoGenomics Appoints Lynn Tetrault Interim CEO

FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,...

NEO : 8.89 (-0.22%)
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

NEO : 8.89 (-0.22%)
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment...

NEO : 8.89 (-0.22%)
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

NEO : 8.89 (-0.22%)
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NEO : 8.89 (-0.22%)
DCPH : 11.43 (+7.63%)
NeoGenomics Reports Revenue of $117 Million in the First Quarter

First-Quarter 2022 Results - Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% - Clinical Services revenue increased 2% to...

NEO : 8.89 (-0.22%)
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay

FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today...

NEO : 8.89 (-0.22%)
Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to Decline

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEO : 8.89 (-0.22%)
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022

Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused...

NEO : 8.89 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

3rd Resistance Point 10.29
2nd Resistance Point 9.82
1st Resistance Point 9.35
Last Price 8.89
1st Support Level 8.41
2nd Support Level 7.94
3rd Support Level 7.47

See More

52-Week High 54.74
Fibonacci 61.8% 36.60
Fibonacci 50% 31.00
Fibonacci 38.2% 25.40
Last Price 8.89
52-Week Low 7.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar